Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Differential Impact of Nevirapine on Artemether-Lumefantrine Pharmacokinetics in Individuals Stratified by CYP2B6 c.516G>T Genotypes.

Antimicrobial agents and chemotherapy - 21 Feb 2020

Abdullahi Sa'ad T, Soyinka Julius O, Olagunju Adeniyi, Bolarinwa Rahman A, Olarewaju Olusola J, Bakare-Odunola Moji T, Winterberg Markus, Tarning Joel, Owen Andrew, Khoo Saye

Abstract excerpt

There is an increased recognition of the need to identify and quantify the impact of genetic polymorphisms on drug-drug interactions. This study investigated the pharmacogenetics of the pharmacokinetic drug-drug interaction between nevirapine and artemether-lumefantrine in HIV-positive and HIV-negative adult Nigerian subjects. Thirty each of HIV-infected patients on nevirapine-based antiretroviral therapy and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP2B6
Share to Genotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Nevirapine

Share to Polymorphism, Genetic

Source

Open in PubMed Open full text

Identifiers

PMID: 31871092
DOI: 10.1128/AAC.00947-19
PMCID: PMC7038275

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Differential Impact of Nevirapine on Artemether-Lumefantrine Pharmacokinetics in Individuals Stratified by CYP2B6 c.516G>T Genotypes.PMID 31871092Read ↗

Role of pharmacogenetics and clinical parameters on nevirapine plasma concertation among HIV-1 patients receiving Antiretroviral Therapy in KenyaSemantic proximity Read ↗

Influence of selected polymorphisms in disposition genes on lumefantrine pharmacokinetics when coadministered with efavirenz.Semantic proximity Read ↗

Pharmacogenetics of CYP2B6, CYP2A6 and UGT2B7 in HIV treatment in African populations: focus on efavirenz and nevirapine.Semantic proximity Read ↗

Pharmacogenetics of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in resource-limited settings: Influence on antiretroviral therapy response and concomitant anti-tubercular, antimalarial and contraceptive treatments.Semantic proximity Read ↗

Genetics of Nevirapine Metabolic Pathways at Steady State in HIV-Infected Cambodians.Semantic proximity Read ↗

CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients.Semantic proximity Read ↗

The dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and disposition.Semantic proximity Read ↗

Effects of CYP2B6 and CYP1A2 Genetic Variation on Nevirapine Plasma Concentration and Pharmacodynamics as Measured by CD4 Cell Count in Zimbabwean HIV-Infected Patients.Semantic proximity Read ↗

Prevalence of Cytochrome P450 2B6 Single Nucleotide Polymorphism in an HIV-Positive Cohort in Jos, Nigeria: Implication for HIV Therapy.Semantic proximity Read ↗

Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians.Semantic proximity Read ↗

Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda.Semantic proximity Read ↗

A Review of Pharmacogenetics of Antimalarials and Associated Clinical Implications.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.